Generate Biomedicines, Inc. is a pioneering biotechnology company at the forefront of AI-driven protein therapeutics discovery and development. It owes its origins to federally funded research – supported by the National Science Foundation and the National Institutes of Health – that was conducted at Dartmouth College.
Generate Biomedicines, Inc. brings together groundbreaking machine learning and biological engineering technology to help create breakthrough medicines. Its Generate Platform can quickly and accurately design medicines on demand for a wide range of therapies.
Generate Biomedicines, located in Somerville, Massachusetts, employs 325 people and drives consistent economic growth by attracting and retaining a highly skilled biotechnology and artificial intelligence workforce. The company’s AI-based platform also opens new markets for precision medicine, attracting significant investment and enhancing global competitiveness. The company raised $370 million in its Series B financing in November 2021, followed by a $273 million Series C round in September 2023, with new investors including Amgen, NVIDIA’s venture capital arm, and Samsung’s Life Science Fund joining in December 2024.
Dartmouth College is a vital contributor to economic growth through its focus on federally funded research and technology transfer. The college’s entrepreneurial ecosystem, anchored in its Office of Entrepreneurship and Technology Transfer, fosters the transformation of federally funded scientific discoveries into viable enterprises like Generate Biomedicines, bolstering the local, state, and national economy.